CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Coronavirus has an impact on clinical trial participants
Cancer clinical trials and COVID-19 (Coronavirus)
As the health care systems in Canada ramp up to meet the coming COVID-19 (Coronavirus) challenges, the Canadian Cancer Trials Group (CCTG) recognizes that this may have an impact on the conduct and availability of cancer clinical trials.
People living with cancer are at an increased risk from COVID-19 because of underlying medical conditions and a compromised immune system. Patient care, safety and well-being are a priority while we work to minimize the impact and duration of this pandemic.
Challenges for patients participating in a trial may arise from; social distancing requirements, cancer centre restrictions, travel limitations, interruptions to the supply of investigational products, or because of the strain on hospital resources. These challenges may lead to difficulties in meeting trial-specified procedures, including following trial-mandated visits or follow-up, and access to laboratory or diagnostic testing.
More >>
CCTG Annual Spring Meeting for 2020 has been cancelled
CCTG has continued to monitor the developments pertaining to the coronavirus (COVID-19).
More >>
Cell Therapy’s Promise for Canadians Must Include Access
An emerging form of immunotherapy, called adoptive cell transfer, has the potential to transform the way in which cancers are treated.
More >>
PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020
ENZAMET | CCTG PR17 (NCT02446405) study has been highlighted by the American Society of Clinical Oncology (ASCO) 2020 annual report as a major advance in cancer treatment. The results were first presented at ASCO 2019, the trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer.
More >>
An interview with Senior Investigator Annette Hay
Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials.
More >>
Cell Therapy’s Promise for Canadians Must Include Access
An emerging form of immunotherapy, called adoptive cell transfer, has the potential to transform the way in which cancers are treated.
More >>
Palliative and supportive care presentation at ESMO 2019
Approximately a fifth of patients participating in phase III breast, lung, or colorectal cancer clinical trials conducted by CCTG also used complementary medicines.
More >>Planned trials
GCC1
Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumours
Recently activated
The rise of precision medicine
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
More >>
TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancer
Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.
More >>
Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide
Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.
More >>
Canadian Cancer Research Alliance announces award winners
Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham will receive the Exceptional Leadership in Patient Involvement in Cancer award.
More >>Publications
Optimizing whole brain radiotherapy dose and fractionation: Results from a prospective phase III trial (NCCTG N107C (Alliance)/CEC.3)
International Journal of Radiation Oncology*Biology*Physics 106: 255 - 260, 2020
Trifiletti DM;Ballman KV;Brown PD;Anderson SK;Carrero XW;Cerhan JH;Whitton AC;Greenspoon J;Parney IF;Laack NN;Ashman JB;Bahary JP;Hadjipanayis CG;Urbanic JJ;Barker FG;Farace E;Khuntia D;Giannini C;Buckner JC;Galanis E;Roberge D;
Unusual Carfilzomib Toxicity: Three Cases of Drug-induced Thrombotic Microangiopathy (TMA) after Treatment with High-dose weekly Carfilzomib, Cyclophosphamide, and Dexamethasone (wCCD)
Clinical Lymphoma Myeloma and Leukemia 19: e272 - e273, 2019
Monteith B;Venner C;Reece D;Kew A;Lalancette M;Garland J;Shepherd L;McDonald G;Gul E;Pater J;Hay A;
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
N Engl J Med 381: 121 - 131, 2019
Davis ID;Martin AJ;Stockler MR;Begbie S;Chi KN;Chowdhury S;Coskinas X;Frydenberg M;Hague WE;Horvath LG;Joshua AM;Lawrence NJ;Marx G;McCaffrey J;McDermott R;McJannett M;North SA;Parnis F;Parulekar W;Pook DW;Reaume MN;Sandhu SK;Tan A;Tan TH;Thomson A;Tu E;Vera-Badillo F;Williams SG;Yip S;Zhang AY;Zielinski RR;Sweeney CJ;
Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer (ONLINE)
Clinical epigenetics 11: 155 - 155, 2019
Snider H;Villavarajan B;Peng Y;Shepherd LE;Robinson AC;Mueller CR;
Complementary medicine (CM) use in phase III clinical trials (P3T) conducted by the Canadian Cancer Trials Group (CCTG)
Ann Oncol 30, 2019
Wells JC;Sidhu A;Ding K;Heng DYC;Shepherd F;Ellis PM;Bradbury PA;Jonker DJ;Moore M;Siu LL;Gelmon KA;Karapetis C;Shapiro J;Nott L;O'Callaghan CJ;Parulekar WR;Seymour LK;Smoragiewicz M;Monzon JG;
LBA18Clinical outcomes by chemotherapy regimen in patients with RS 26-100 in TAILORx
Ann Oncol 30, 2019
Sparano J;Gray RJ;Makower D;Albain K;Saphner TJ;Badve S;Wagner L;Mihalcioiu C;Desbiens C;Hayes DF;Dees EC;Geyer C;Olson J;Wood WC;Lively T;Paik S;Ellis M;Abrams JS;Sledge GW;
Canadian cancer trials group trial IND.231: A phase 1 trial evaluating CX-5461, a novel first-in-class G-quadruplex stabilizer in patients with advanced solid tumors enriched for DNA-repair deficiencies
San Antonio Breast Cancer Symposium , 2019
Hilton J;Gelmon K;Cescon D;Tinker A;Jonker D;Goodwin R;Laurie S;Hansen A;Aparicio S;Soong J;Hagerman L;Lui H;Bedard P;Pritchard K;Tu D;Seymour L;
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205
Clinical Genitourinary Cancer 17: 201 - 208, 2019
Hotte SJ;Chi KN;Joshua AM;Tu D;Macfarlane RJ;Gregg RW;Ruether JD;Basappa NS;Finch D;Salim M;Winquist EW;Torri V;North S;Kollmannsberger C;Ellard SL;Eigl BJ;Tinker A;Allan AL;Beja K;Annala M;Powers J;Wyatt AW;Seymour L;